Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Spironolactone and acute mountain sickness

T T Currie, P H Carter, W L Champion

    The Medical Journal of Australia
    |July 31, 1976
    PubMed
    Summary

    Spironolactone effectively prevented acute mountain sickness in adults trekking at high altitudes in Nepal. This study showed a significant reduction in altitude sickness symptoms compared to previous untreated treks.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The Endoscopic Treatment of Chronic Urethritis.

    Atlanta journal-record of medicine·2022
    Same author

    Advice to Gonorrheal Patients.

    Atlanta journal-record of medicine·2022
    Same author

    A Case of Calculus.

    Atlanta journal-record of medicine·2022
    Same author

    Remarks on Gonorrhea.

    Atlanta journal-record of medicine·2022
    Same author

    Prostatic Massage.

    Atlanta journal-record of medicine·2022
    Same author

    The Treatment of Stricture of the Anterior Urethra.

    Atlanta journal-record of medicine·2022

    Area of Science:

    • Altitude sickness research
    • Pharmacological interventions for mountain sickness

    Background:

    • Acute mountain sickness (AMS) is a common condition affecting individuals ascending to high altitudes.
    • Previous trekking experiences at similar altitudes resulted in AMS for some participants.

    Purpose of the Study:

    • To evaluate the prophylactic efficacy of spironolactone against acute mountain sickness.
    • To assess the impact of spironolactone on trekkers at high altitudes in Nepal.

    Main Methods:

    • A group of thirteen adults received spironolactone (25 mg three times daily) before and during high-altitude exposure (4,300 m to 5,500 m).
    • A retrospective comparison was made with the same individuals' previous trekking experiences without prophylactic treatment.

    Main Results:

    Related Experiment Videos

    • All thirteen participants remained free from acute mountain sickness during the spironolactone prophylaxis phase.
    • In contrast, five of these individuals had previously experienced AMS at similar altitudes without treatment.

    Conclusions:

    • Spironolactone demonstrated significant effectiveness as a prophylactic agent for preventing acute mountain sickness.
    • High-altitude trekking can be undertaken without AMS symptoms when using spironolactone medication.